Search company, investor...

Total Raised

$177.5M

Investors Count

9

Deal Terms

1

Funding, Valuation & Revenue

8 Fundings

Endologix has raised $177.5M over 8 rounds.

Endologix's latest funding round was a Take Private for on October 1, 2020.

Endologix's 2017 revenue was >$100M. Endologix's most recent revenue is from 2017.

Sign up for a free demo to see revenue data from 2017 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

10/1/2020

Take Private

$99M

0

FY undefined

3

5/3/2020

Loan - II

$99M

$99M

0

FY undefined

10

4/4/2017

Line of Credit

$99M

$99M

>$100M

FY 2017

10

4/4/2017

Loan

$99M

$99M

$0.00B

((9.99x))

FY 1234

10

10/13/2010

PIPE - III

$99M

$99M

0

FY undefined

0

Date

10/1/2020

5/3/2020

4/4/2017

4/4/2017

10/13/2010

Round

Take Private

Loan - II

Line of Credit

Loan

PIPE - III

Amount

$99M

$99M

$99M

$99M

Investors

Valuation

$99M

$99M

$99M

$99M

$99M

Revenue

0

FY undefined

0

FY undefined

>$100M

FY 2017

$0.00B

((9.99x))

FY 1234

0

FY undefined

Sources

3

10

10

10

0

You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo
CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Endologix Deal Terms

1 Deal Term

Endologix's deal structure is available for 1 funding round, including their PIPE from July 01, 1998.

Round

PIPE

Funding Date

$99M

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

Board Voting

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

PIPE

$99M

$99M

$99M

$99M

Endologix Investors

9 Investors

Endologix has 9 investors. Deerfield Management invested in Endologix's Take Private funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

4/4/2017

10/1/2020

3
Line of Credit, Loan (2017), Take Private (2020)

Venture Capital

New York

00/00/0000

00/00/0000

Paycheck Protection Program

Subscribe to see more

Government

DC

00/00/0000

00/00/0000

EW Healthcare Partners

Subscribe to see more

Growth Equity

New York

00/00/0000

00/00/0000

Wasatch Advisors

Subscribe to see more

Asset/Investment Management

Utah

00/00/0000

00/00/0000

UBS

Subscribe to see more

Investment Bank

Switzerland

First funding

4/4/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Last Funding

10/1/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Investor

Paycheck Protection Program

EW Healthcare Partners

Wasatch Advisors

UBS

Rounds

3
Line of Credit, Loan (2017), Take Private (2020)

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

Type

Venture Capital

Government

Growth Equity

Asset/Investment Management

Investment Bank

Location

New York

DC

New York

Utah

Switzerland

Endologix Acquisitions

3 Acquisitions

Endologix acquired 3 companies. Their latest acquisition was PQ Bypass on April 13, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

4/13/2021

Series C

$99M

$87.49M

Acquired

5

2/3/2016

Series E+

Subscribe to see more

$99M

$99M

Subscribe to see more

10

12/13/2010

Debt

Subscribe to see more

$99M

$99M

Subscribe to see more

0

Date

4/13/2021

2/3/2016

12/13/2010

Investment Stage

Series C

Series E+

Debt

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Total Funding

$87.49M

$99M

$99M

Note

Acquired

Subscribe to see more

Subscribe to see more

Sources

5

10

0

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Compare Endologix to Competitors

V
Varix Medical

Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.

T
TriReme Medical

TriReme Medical is a privately held medical device company dedicated to the development, manufacturing, and commercialization of next generation percutaneous devices for the treatment of complex coronary and peripheral arterial disease. The company is focused on the US and the emerging Asian markets.

I
Intersect Partners

Intersect Partners specializes in transforming innovative ideas into medical products within the healthcare sector. They offer services that guide concepts through the development process to become market-ready medical solutions. It is based in San Clemente, California.

D
DuoCore

DuoCure offers intraluminal minimally invasive implantable device for treatment of obesity.

N
Neocrin

Researcher and developer of a minimally invasive, encapsulated cellular transplant device for the treatment of diabetes. The company sold its assets to Novocell.

Monteris Medical Logo
Monteris Medical

Monteris Medical is a neurosurgical company that operates in the healthcare industry. The company offers a minimally invasive, robotically controlled laser thermal therapy system that uses MRI-guided laser light to destroy unwanted tissue in the brain, such as tumors and lesions. Monteris primarily serves the healthcare sector, particularly neurosurgery. It was founded in 1999 and is based in Hopkins, Minnesota.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.